Tumor lysis syndrome: An uncommon complication of fludarabine therapy of chronic lymphocytic leukemia

Journal of Clinical Oncology

Volumn 16, Issue 7, 1998, Pages 2313-2320

  Cheson, Bruce D ^a   Frame, James N ^b   Vena, Don ^b   Quashu, Nadine ^b   Sorensen, J Mel ^b  

^a NATIONAL CANCER INSTITUTE   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALKYLATING AGENT; ALLOPURINOL; ANTINEOPLASTIC AGENT; CLADRIBINE; FLUDARABINE; NUCLEOSIDE ANALOG; PENTOSTATIN;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL ARTICLE; DIAGNOSTIC APPROACH ROUTE; DRUG MONITORING; DRUG RESPONSE; FEMALE; HEMATOLOGIC DISEASE; HUMAN; HUMAN TISSUE; INFECTION; KIDNEY FAILURE; LABORATORY TEST; LYMPHOPROLIFERATIVE DISEASE; MALE; PATIENT CODING; PRIORITY JOURNAL; QUESTIONNAIRE; TREATMENT OUTCOME;

EID: 0031831522     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1998.16.7.2313     Document Type: Article

References (41)

1. Arseneau JC, Bagley CM, Anderson T, et al: Hyperkalemia, a sequel to chemotherapy of Burkitt's lymphoma. Lancet 1:10-14, 1973
2. Zusman J, Brown DM, Nesbit ME: Hyperphosphatemia, hyperphosphaturia and hypocalcemia in acute lymphoblastic leukemia. New Engl J Med 289:1335-1340, 1973
3. Arseneau JC, Canellos GP, Banks PM, et al: American Burkitt's lymphoma: A clinicopathologic study of 30 cases. I. Clinical factors relating to prolonged survival. Am J Med 58:314-321, 1975
4. Cohen LF, Balow JE, Magrath IT, et al: Acute tumor lysis syndrome: A review of 37 patients with Burkitt's lymphoma. Am J Med 68:486-491, 1980
5. Lorigan PC, Woodings PL, Morgenstern GR, et al: Tumour lysis syndrome, case report and review of the literature. Ann Oncol 7:631-636, 1996
6. Morse BM, Shattil SJ: Metabolic complications of aggressive therapy of chronic lymphocytic leukemia. Am J Med Sci 276:311-314, 1974
7. Kurlander R, Stein RS, Roth D: Hyperkalemia complicating splenic irradiation of chronic lymphocytic leukemia. Cancer 36:926-930, 1975
8. Boccia RV, Longo DL, Liever ML, et al: Multiple recurrences of acute tumor lysis syndrome in an indolent non-Hodgkin's lymphoma. Cancer 56:2295-2297, 1985
9. Gomez GA, Han T: Acute tumor lysis syndrome in prolymphocytic leukemia. Arch Intern Med 147:375-376, 1987
10. McCroskey RD, Mosher DF, Spencer CD, et al: Acute tumor lysis syndrome and treatment response in patients treated for refractory chronic lymphocytic leukemia with short-course, high-dose cytosine arabinoside, cisplatin, and etoposide. Cancer 66:246-250, 1990
11. Nomdedéu J, Martino R, Sureda A, et al: Acute tumor lysis syndrome complicating conditioning therapy for bone marrow transplantation in a patient with chronic lymphocytic leukemia. Bone Marrow Transplant 13:659-660, 1994
12. Grever MR, Kopecky KJ, Coltman CA, et al: Fludarabine monophosphate: A potentially useful agent in chronic lymphocytic leukemia. Nouv Rev Fr Hematol 30:457-459, 1988
13. Keating MJ, Kantarjian H, Talpaz M, et al: Fludarabine: A new agent with major activity against chronic lymphocytic leukemia. Blood 74:19-25, 1989
14. Redman JR, Cabanillas F, Velasquez WS, et al: Phase II trial of fludarabine phosphate in lymphoma: An effective new agent in low-grade lymphoma. J Clin Oncol 10:790-794, 1992
15. Cheson BD: New chemotherapeutic agents for the treatment of low-grade non-Hodgkin's lymphomas. Semin Oncol 20:96-110, 1993
16. Sorensen JM, Vena D, Fallavollita A, et al: Treatment of refractory chronic lymphocytic leukemia with fludarabine phosphate via the Group C mechanism of the National Cancer Institute: 5-year follow-up report. J Clin Oncol 15:458-465, 1997
17. Cheson BD: Immunologic and immunosuppressive complications of purine analogue therapy. J Clin Oncol 13:2431-2448, 1995
18. Cheson BD, Vena D, Foss F, et al: Neurotoxicity of purine analogs: A review. J Clin Oncol 12:2216-2228, 1994
19. Elias L, Stock-Novack D, Head DR, et al: A phase I trial of combination fludarabine monophosphate and chlorambucil in chronic lymphocytic leukemia: A Southwest Oncology Group study. Leukemia 7:361-365, 1993
20. List AF, Kummet TD, Adams JD, et al: Tumor lysis syndrome complicating treatment of chronic lymphocytic leukemia with fludarabine phosphate. Am J Med 89:388-390, 1990
21. Cannon LM, Spilove L, Rhodes R, et al: Acute tumor lysis syndrome complicating fludarabine treatment of prolymphocytic leukemia. Conn Med 57:651-654, 1993
22. Fenchel K, Bergmann L, Jahn B, et al: Fludarabine phosphate in refractory chronic lymphocytic leukemia. Onkologie 14:190, 1991 (suppl 2; abstr 546)
23. Nakhoul F, Green J, Abassi ZA, et al: Tumor lysis syndrome induced by fludarabine monophosphate: A case report [letter]. Eur J Haematol 56:254-255, 1996
24. Rai KR: A critical analysis of staging in CLL, in Gall RP, Rai KR (eds): Chronic Lymphocytic Leukemia. Recent Progress and Future Directions. New York, NY, Alan R. Liss, 1987, p 253
25. Cheson BD, Bennett JM, Rai KR, et al: Guidelines for clinical protocols for chronic lymphocytic leukemia: Report of the NCI-sponsored Working Group. Am J Hematol 29:152-163, 1988
26. Wittes RE: Manual of Oncologic Therapeutics: 1991/1992. Journal 446-448, 1991
27. Lehmann EL: Nonparametrics: Statistical Methods Based on Ranks. San Francisco, CA, Holden Day, Inc, 1975
28. Rozman C, Montserrat E, Rodríguez-Fernández JM, et al: Bone marrow histologic pattern - the best single prognostic parameter in chronic lymphocytic leukemia: A multivariate survival analysis of 329 cases. Blood 64:642-648, 1984
29. Keating MJ, Kantarjian H, O'Brien S, et al: Fludarabine: A new agent with marked cytoreductive activity in untreated chronic lymphocytic leukemia. J Clin Oncol 9:44-49, 1991
30. O'Brien S, Kantarjian H, Beran M, et al: Results of fludarabine and prednisone therapy in 264 patients with chronic lymphocytic leukemia with multivariate analysis-derived prognostic model for response to treatment. Blood 82:1695-1700, 1993
31. Rai KR, Peterson B, Elias L, et al: A randomized comparison of fiudarabine and chlorambucil for patients with previously untreated chronic lymphocytic leukemia. A CALGB, SWOG. CTC/NCI-C and ECOG inter-group study. Blood 88:141a, 1996 (abstr 552)
32. French Cooperative Group on CLL, Johnson S, Smith AG, et al: Multicentre prospective randomised trial of fiudarabine versus cyclophosphamide, doxorubicin, and prednisone (CAP) for treatment of advanced-stage chronic lymphocytic leukemia. Lancet 347:1432-1438, 1996
33. Cheson BD: Toxicities of nucleoside analogs, in Cheson BD, Keating MJ, Plunkett W (eds): Nucleoside Analogs in Cancer Therapy. New York, NY, Marcel Dekker, Inc, 1997, pp 415-459
34. Cheson BD, Vena D, Freidlin B, et al: The risk of secondary malignancies following purine analog therapy of chronic lymphocytic leukemia (CLL) and hairy cell leukemia (HCL). Proc Am Soc Clin Oncol 16:15a, 1997 (abstr 52)
35. Killick S, Mercieca J, Nandi A, et al: Fludarabine-induced tumour lysis in low grade non-Hodgkin's lymphoma. Clin Lab Haematol 19:79-80, 1997
36. Puccio CA, Mittelman A, Lichtman SM, et al: A loading dose/continuous infusion schedule of fludarabine phosphate in chronic lymphocytic leukemia. J Clin Oncol 9:1562-1569, 1991
37. Bergmann L, Fenchel K, Jahn B, et al: Immunosuppressive effects and clinical response of fludarabine in refractory chronic lymphocytic leukemia. Ann Oncol 4:371-375, 1993
38. El'Agnaf MR, Ennis KE, Morris TCM, et al: Successful remission induction with deoxycoformycin in elderly patients with T-helper prolymphocytic leukaemia. Br J Haematol 63:93-104, 1986
39. Dann EJ, Gillis S, Polliack A, et al: Brief report: Tumor lysis syndrome following treatment with 2-chlorodeoxyadenosine for refractory chronic lymphocytic leukemia. New Engl J Med 329:1547-1548, 1993
40. Vahdat L, Wong ET, Wile MJ, et al: Therapeutic and neurotoxic effects of 2-chlorodeoxyadenosine in adults with acute myeloid leukemia. Blood 84:3429-3434, 1994
41. Spielberger RT, Larson RA, O'Brien SM, et al: Phase I study of 2-chlorodeoxyadenosine (CdA) by 1 hour bolus infusion in hematologic malignancies. Proc Am Soc Clin Oncol 12:140a, 1993 (abstr 359)